ION Breast Cancer Clinical Pathways - ION Solutions

More documents

Recommendations

Info

Lung CancerPage 38 of 39© 2013 by ION Solutions. All rights reserved
DisclaimerClinical pathways document potential steps in the diagnosis and treatment of acondition or procedure for individual patients. These are predominantlymanagement tools and are based on clinical information developed in otherguidelines or parameters and agreed upon by the participating physicians of thisclinical steering committee. They are specific to this group.The information provided in this document is in no way fully comprehensive.Pathways may not be appropriate for use in all circumstances, nor are they asubstitute for the practitioner’s experience and judgment. Their applicability mustbe assessed by the responsible practitioner in light of relevant circumstancespresented by individual patients. Optimal treatment for every individual patientshould be specifically prescribed by the patient’s treating physician. The viewsexpressed in these clinical pathways are those of the authors and do notnecessarily reflect policies and/or official positions of ION Solutions. As aPractitioner you acknowledge that your use of any of the clinical pathwaysprovided to you is based solely upon your independent clinical judgment, andneither ION Solutions nor the physicians who participated in the clinical steeringcommittee are liable for decisions made or actions taken by following thesepathways or any of the information contained herein.Page 39 of 39© 2013 by ION Solutions. All rights reserved
Page 1 and 2: ION SolutionsNational Physician Net
Page 3: Best Supportive Care and/or Hospice
Page 6 and 7: Chemotherapy:Taxotere (Docetaxel) A
Page 8 and 9: Taxotere (Docetaxel) Paraplatin (Ca
Page 10 and 11: Taxotere (Docetaxel) EP=Low; FN=10%
Page 12 and 13: Herceptin (Trastuzumab) Followed by
Page 14 and 15: Herceptin (Trastuzumab) Taxotere (D
Page 16 and 17: Colon: First Line MetastaticChemoth
Page 18 and 19: 5-FU (5-Fluorouracil) Leucovorin +/
Page 20 and 21: Note: Wild Type KRAS documentation
Page 22 and 23: Camptosar (Irinotecan) Avastin (Bev
Page 24 and 25: Adjuvant Non-Small Cell Lung (NSCL)
Page 26 and 27: Paraplatin (Carboplatin) Taxotere (
Page 28 and 29: Best Supportive Care and/or Hospice
Page 30 and 31: Clinical Trial:Screen patient for c
Page 32 and 33: Small Cell Lung: Extensive Disease
Page 34 and 35: Paraplatin (Carboplatin) VP-16 (Eto
Page 36 and 37: Anti-EmeticsEmetogenic Risk:High Em

ION Breast Cancer Clinical Pathways - ION Solutions

Create successful ePaper yourself

Delete template?

Save as template?